Chewy (CHWY) Q2 2026 Earnings Call Transcript

Chewy reported Q2 FY2026 net sales of $3.33 billion, up 7.3% year over year, and adjusted EBITDA margin of 6.8%, up 90bps and above its 6.3%-6.4% guidance range; adjusted EPS was $0.36. The company raised the low end of full-year EBITDA-margin guidance to 6.7%-6.8%, implying more than 100bps of expansion at the midpoint, while guiding FY2026 revenue to $13.46-$13.57 billion, or 6.8%-7.7% growth. Results were supported by 9.3% Autoship growth to $2.8 billion, 3.8% active-customer growth to 21.7 million, automation and sponsored ads, though roughly $10 million of Q2 upside came from timing-related tariff refunds and consumer discretionary spending remains pressured. Chewy expects AI initiatives to generate low-tens-of-millions in FY2026 savings and roughly $50 million annualized in FY2027, alongside contributions above expectations from the $400 million Modern Animal acquisition and SmartPak.

Analysis

CHWY’s key re-rating question is whether investors capitalize the current margin improvement as durable rather than cyclical. The reported quarterly beat was largely non-recurring, but the more investable signal is the combination of automation, advertising monetization, and healthcare mix shifting the incremental-margin profile upward. If management can sustain roughly 100bp of annual EBITDA-margin expansion while holding customer-acquisition spending efficient, consensus may still be underestimating FY27 EBITDA and FCF conversion.

The near-term setup is less clean than the headline suggests: Q3 margin guidance embeds normalization of favorable items and heavier brand spend, while core organic growth remains mid-single digits in a low-price, weak-discretionary environment. That creates risk of a post-earnings fade if sell-side estimates extrapolate the quarter’s margin rate. The principal falsifiers are organic growth falling below the guided 5.3%-6.2% Q3 range, deterioration in active-customer additions/Autoship growth, or Modern Animal remaining dilutive beyond the planned integration period.

The non-obvious upside is strategic: a health-linked Chewy Plus redesign can turn veterinary care from a standalone growth investment into a retention and basket-building tool, raising lifetime value across pharmacy, food and Autoship. That would pressure pet-specialty retailers without comparable first-party transaction data or recurring digital relationships, particularly Petco (WOOF), while also reducing CHWY’s dependence on new pet formation. Conversely, the $400m acquisition plus new debt makes returns on clinic expansion more important; a slower consumer backdrop could expose a mismatch between fixed clinical capacity and demand.

Consensus may be too focused on AI savings as a direct margin windfall. The better interpretation is that savings protect margins while CHWY increases customer acquisition and loyalty investment; this is bullish for share gains but limits near-term EBITDA upside. The stock merits accumulation on any margin-normalization-driven weakness rather than chasing an earnings-day move.

Key Decisions for Investors

• Accumulate CHWY on a 5%-10% post-results pullback over the next 1-3 months; target a rerating as FY27 estimates incorporate structural SG&A leverage and health/advertising mix. Risk/reward is favorable only if Q3 organic growth remains within guidance and Autoship continues to outgrow sales.
• Use a 6-12 month pair: long CHWY / short WOOF, sized beta-neutral. CHWY’s recurring digital relationship and health integration should capture share while WOOF has greater exposure to discretionary store traffic and less obvious operating-leverage support; exit if CHWY’s active-customer growth decelerates materially or WOOF demonstrates sustained comparable-sales acceleration.
• Do not underwrite the full AI savings target into FY27 EPS yet. Set an alert for evidence that customer-care self-service expands without worsening service metrics, and for pharmacy/fulfillment labor savings in reported SG&A; absent those disclosures, treat AI as margin protection rather than incremental upside.
• Watch Q3 marketing intensity and the Chewy Plus rollout as a catalyst/risk event. Strong adoption with stable contribution margins would validate higher customer lifetime value; a meaningful rise in marketing as a percent of sales without accelerating net adds would argue for reducing exposure.